Breaking News Instant updates and real-time market news.

BHC

Bausch Health

$23.74

0.435 (1.87%)

06:39
11/30/18
11/30
06:39
11/30/18
06:39

Bausch Health price target raised to $38 from $35 at Mizuho

Mizuho analyst Irina Koffler raised her price target for Bausch Health Companies to $38 and reiterates a Buy rating on the shares following investor conferences with management. The analyst updated her model to include the expected $100M headwind in Q4 from the company's CORE initiative. The analyst views 2019 consensus estimates as too high but thinks Bausch is likely to pursue a near-term tuck-in deal to close the gap.

  • 15

    Feb

BHC Bausch Health
$23.74

0.435 (1.87%)

11/19/18
WELS
11/19/18
NO CHANGE
WELS
Underperform
Wells says Aemcolo approval step toward eventual slowdown for Bausch's Xifaxan
Wells Fargo analyst David Maris noted that Cosmo Pharmaceuticals received approval of Aemcolo for traveler's diarrhea after the close on Friday, November 16. Bausch Health has previously indicated that traveler's diarrhea accounted for less than 10% of Xifaxan sales and they do not see approval of a competing product in TD alone as significant, though Maris said he disagrees with that assessment. He also believes this approval means Aemcolo is more likely to be approved in IBS-D. Maris, who views this news as the first step toward an eventual slowdown, and potentially a decline, in revenues for Xifaxan, keeps an Underperform rating on Bausch Health shares.
11/06/18
WELS
11/06/18
NO CHANGE
WELS
Underperform
Bausch Health continues to underspend on R&D to fuel upside, says Wells Fargo
Wells Fargo analyst David Maris said Bausch Health has been underspending on R&D to help fuel better than expected results and Q3 "was not different" in that respect. Of note, Bausch also announced it is starting an ongoing efficiency initiative, which would proactively reduce channel inventory in Q4. Maris continues to see Bausch Health shares carrying too much risk to recommend and keeps an Underperform rating on the stock.
11/05/18
11/05/18
UPGRADE
Target $32

Overweight
Bausch Health upgraded to Overweight on improving growth at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Bausch Health to Overweight from Equal Weight, as he expects improved growth in 2020, a mix shift toward new products and gradual debt paydown to drive the stock's multiple higher. He continues to project Q3 EBITDA of $850M, 5% above consensus, and sees the upcoming quarterly report as a potential catalyst to drive the stock up, Risinger added. He set a $32 price target on Bausch Health shares.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Bausch Health upgraded to Overweight from Equal Weight at Morgan Stanley

TODAY'S FREE FLY STORIES

ALB

Albemarle

$67.72

-0.29 (-0.43%)

05:37
11/12/19
11/12
05:37
11/12/19
05:37
Downgrade
Albemarle rating change  »

Albemarle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.86

0.11 (0.62%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Cellular Biomedicine rating change  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNIRF

Senior plc

$0.00

(0.00%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Senior plc rating change  »

Senior plc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:34
11/12/19
11/12
05:34
11/12/19
05:34
Upgrade
Solvay rating change  »

Solvay upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BOX

Box

$16.45

-0.495 (-2.92%)

05:32
11/12/19
11/12
05:32
11/12/19
05:32
Downgrade
Box rating change  »

Box downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

CTVA

Corteva

$26.74

0.54 (2.06%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Initiation
Corteva initiated  »

Corteva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

IFJPY

Informa

$0.00

(0.00%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Upgrade
Informa rating change  »

Informa upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPKFF

LPKF Laser & Electronics

$0.00

(0.00%)

05:29
11/12/19
11/12
05:29
11/12/19
05:29
Downgrade
LPKF Laser & Electronics rating change  »

LPKF Laser &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$91.87

-0.35 (-0.38%)

05:28
11/12/19
11/12
05:28
11/12/19
05:28
Downgrade
Eaton rating change  »

Eaton downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 19

    Nov

COVTY

Covestro

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Downgrade
Covestro rating change  »

Covestro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPRUY

Kering

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Upgrade
Kering rating change  »

Kering upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$16.11

-0.1 (-0.62%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Fiat Chrysler rating change  »

Fiat Chrysler upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Peugeot rating change  »

Peugeot upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$0.42

0.0385 (10.13%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Conference/Events
Ageagle Aerial Systems to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

NNGRY

NN Group

$0.00

(0.00%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Downgrade
NN Group rating change  »

NN Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:23
11/12/19
11/12
05:23
11/12/19
05:23
Earnings
Embraer backs FY20 revenue view of $2.5B-$2.8B »

May not compare to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PRBZF

Premium Brands

$0.00

(0.00%)

05:22
11/12/19
11/12
05:22
11/12/19
05:22
Downgrade
Premium Brands rating change  »

Premium Brands downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Earnings
Embraer backs FY19 revenue guidance of $5.3M-$5.7M, consensus $5.37M »

Embraer reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

OZMLF

Oz Minerals

$0.00

(0.00%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Downgrade
Oz Minerals rating change  »

Oz Minerals downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.14

(0.00%)

05:20
11/12/19
11/12
05:20
11/12/19
05:20
Conference/Events
Sesen Bio to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:19
11/12/19
11/12
05:19
11/12/19
05:19
Earnings
Embraer reports Q3 EPS (26c), consensus (9c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

AAXN

Axon

$64.41

-0.95 (-1.45%)

05:18
11/12/19
11/12
05:18
11/12/19
05:18
Recommendations
Axon analyst commentary  »

Axon price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

INFO

IHS Markit

$68.90

-0.72 (-1.03%)

05:18
11/12/19
11/12
05:18
11/12/19
05:18
Conference/Events
IHS Markit to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PLNT

Planet Fitness

$67.73

-0.7 (-1.02%)

05:16
11/12/19
11/12
05:16
11/12/19
05:16
Recommendations
Planet Fitness analyst commentary  »

Planet Fitness price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:15
11/12/19
11/12
05:15
11/12/19
05:15
General news
Breaking General news story  »

Federal Reserve Board of…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.